Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Allergenic extract of Chortoglyphus arcuatus: in vivo determination of allergenic potency in histamine equivalent units (HEP)
2005-001194-96Phase 2Active
- Sponsor
- LETI Pharma
- Start
- Mar 2007
- Modality
- Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of chortoglyphus arcuatus allergenic extract in allergic rhinitis (AR), allergic asthma and house dust mite allergy, sponsored by LETI Pharma. Primary endpoint: Skin wheal size after Chortoglyphus arcuatus prick test. Started Mar 2007; status: active.
02
Drugs
chortoglyphus arcuatus allergenic extract
03
Conditions
allergic rhinitis (AR)allergic asthmahouse dust mite allergy
Beyond the preview
Go deeper on 2005-001194-96.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2005-001194-96.